OPKO HEALTH INC
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
OPK$1.710.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| For the years ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities: | |||
| Net loss | $(188,863) | $(328,405) | $(30,143) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 105,297 | 108,655 | 78,716 |
| Non-cash interest | 2,750 | 2,750 | 9,389 |
| Amortization of deferred financing costs | 1,222 | 1,161 | 785 |
| Losses from investments in investees | 107 | 383 | 629 |
| Equity-based compensation – employees and non-employees | 11,413 | 18,509 | 13,632 |
| Non-cash revenue from the transfer of intellectual property | — | — | (3,801) |
| Realized loss (gain) on disposal of fixed assets and sales of equity securities | 1,321 | (455) | (33,922) |
| Loss on conversion of the 2025 Notes | — | — | 11,111 |
| Change in fair value of equity securities and derivative instruments | 17,647 | 153,835 | 3,967 |
| Change in fair value of contingent consideration | (1,036) | (1,312) | (1,703) |
| Gain on sale of GeneDx | — | (18,559) | — |
| Deferred income tax provision | 146 | (74,405) | 10,159 |
| Changes in assets and liabilities, net of the effects of acquisitions: | |||
| Accounts receivable, net | 3,411 | 128,602 | 5,232 |
| Inventory, net | 15,197 | 13,662 | 30,684 |
| Other current assets and prepaid expenses | 7,164 | (3,416) | 1,478 |
| Other assets | (288) | 1,935 | 260 |
| Accounts payable | 2,828 | (9,388) | (10,847) |
| Foreign currency measurement | (1,036) | 2,369 | 2,345 |
| Contract liabilities | (131) | (329) | (15,911) |
| Accrued expenses and other liabilities | (5,346) | (90,781) | (33,723) |
| Net cash (used in) provided by operating activities | (28,197) | (95,189) | 38,337 |
| Cash flows from investing activities: | |||
| Investments in investees | (5,000) | — | (2,000) |
| Proceeds from sale of investments | 364 | 115,423 | 8,079 |
| Acquisition of businesses, net of cash acquired | — | (1,758) | (4,000) |
| Proceeds from the sale of property, plant and equipment | 2,713 | 1,951 | 66,026 |
| Capital expenditures | (16,275) | (24,578) | (32,156) |
| Net cash (used in) provided by investing activities | (18,198) | 91,038 | 35,949 |
| Cash flows from financing activities: | |||
| Debt issuance costs | — | — | (188) |
| Net activity from the exercise of common stock options and warrants | (272) | (774) | 1,081 |
| Borrowings on lines of credit | 671,678 | 1,059,519 | 1,684,713 |
| Repayments of lines of credit | (679,709) | (1,035,774) | (1,695,956) |
| Redemption of 2033 Senior Notes | (3,000) | — | — |
| Net cash (used in) provided by financing activities | (11,303) | 22,971 | (10,350) |
| Effect of exchange rate changes on cash and cash equivalents | 388 | (339) | (1,437) |
| Net increase (decrease) in cash and cash equivalents | (57,310) | 18,481 | 62,499 |
| Cash and cash equivalents at beginning of period | 153,191 | 134,710 | 72,211 |
| Cash and cash equivalents at end of period | $95,881 | $153,191 | $134,710 |
| SUPPLEMENTAL INFORMATION: | |||
| Interest paid | $8,135 | $7,420 | $8,515 |
| Income taxes paid, net of refunds | $3,712 | $8,037 | $5,969 |
| Operating lease right-of-use assets obtained in exchange for lease obligations | $29,363 | $— | $6,493 |
| Assets acquired by finance leases | $203 | $4,717 | $— |
| Non-cash financing: | |||
| Shares issued upon the conversion of: | |||
| 2025 convertible Notes | $— | $— | $68,775 |
| Common Stock options and warrants, surrendered in net exercise | $301 | $1,268 | $— |
| Issuance of common stock for acquisition of ModeX | $— | $221,662 | $— |
| Fair value of shares included in consideration from GeneDx Holdings | $6,689 | $172,000 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.